Olverembatinib Plus Venetoclax and Dexamethasone for Treatment-naïve Ph+ Acute Lymphoblastic Leukemia

Air Force Military Medical University of People's Liberation Army

Status and phase: Enrolling; Phase 2; Phase 1

Conditions: Newly-diagnosed Ph+ Acute Lymphoblastic Leukemia

Treatments: Drug: Olverembatinib plus venetoclax and dexamethasone

Study type: Interventional

Funder types: Other

Identifiers

NCT06082934

20232082

Details and patient eligibility

About

The purpose of this study is to explore the efficacy and safety of the OVD chemotherapy-free regimen (Olverembatinib, venetoclax and dexamethasone) in patients with newly-diagnosed Ph+ALL.

Full description

PRIMARY OBJECTIVES:

To determine the Complete remission (CR) and complete remission with incomplete hematologic recovery (CRi) rates, the measurable residual disease (MRD) rates, the complete molecular remissions (CMR) rates and the progression-free survival (PFS) of the OVD chemotherapy-free regimen (Olverembatinib, venetoclax and dexamethasone) in patients with newly-diagnosed Ph+ALL.

SECONDARY OBJECTIVES:

To describe the toxicities of the OVD regimen. To assess the quality of life and overall survival of the OVD chemotherapy-free regimen in patients with newly-diagnosed Ph+ALL.

Enrollment: 30 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Diagnosis of newly-diagnosed Ph+ acute lymphoblastic leukemia
• Age >= 18
• Adequate hepatic function
• Adequate renal function
• Adequate heart function
• Life expectancy of more than 3 months
• Women of child-bearing potential and men with partners of child-bearing potential must agree to use 2 methods of birth control or be surgically sterile or abstain from heterosexual activity from the time of signing the informed consent for through 120 days after the last dose of study medication.
• Women of childbearing potential have negative pregnancy test within 72 hours of initiating study drug dosing.
• Male subjects must agree to use a latex condom during sexual contact with females of childbearing potential even if they have had a successful vasectomy starting with the first dose of study therapy through 120 days after the last dose of study therapy.
• All subjects must be counseled at a minimum of every 28 days about pregnancy precautions and risks of fetal exposure.
• Females of reproductive potential must adhere to the scheduled pregnancy testing as required in the POMALYST REMS program.

Exclusion criteria

• Current or anticipated use of other investigational agents.
• Female patients who are lactating or have a positive serum pregnancy test during the screening period.
• Major surgery within 3 weeks prior to first dose
• Acute active infection requiring systemic antibiotics, antivirals, or antifungals within two weeks prior to first dose
• Known or suspected HIV infection, known HIV seropositivity
• Active hepatitis infection
• Has known chronic obstructive pulmonary disease with a forced expiratory volume in 1 second (FEV1) <50% of predicted normal
• Known gastrointestinal disease or procedure that could interfere with the oral absorption or tolerance, including difficulty swallowing

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

30 participants in 1 patient group

OVD regimen of Olverembatinib plus venetoclax and dexamethasone

Experimental group

Description:

Olverembatinib: orally every other day at a dose of 40mg Venetoclax: in a daily ramp-up strategy (100 mg d4, 200 mg d5, 400 mg d6-17) Dexamethasone: intravenously 10mg, d1-14, 5mg, d15-28

Treatment:

Drug: Olverembatinib plus venetoclax and dexamethasone